239 related articles for article (PubMed ID: 8107743)
1. Racial differences in the use of drug therapy for HIV disease in an urban community.
Moore RD; Stanton D; Gopalan R; Chaisson RE
N Engl J Med; 1994 Mar; 330(11):763-8. PubMed ID: 8107743
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.
Sackoff J; McFarland J; Su S; Bryan E
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):387-92. PubMed ID: 9833748
[TBL] [Abstract][Full Text] [Related]
7. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
8. Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS).
Solomon L; Stein M; Flynn C; Schuman P; Schoenbaum E; Moore J; Holmberg S; Graham NM
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):253-61. PubMed ID: 9495226
[TBL] [Abstract][Full Text] [Related]
9. Evaluating HIV/AIDS disparities for blacks in the United States: a review of antiretroviral and mortality studies.
Oramasionwu CU; Brown CM; Lawson KA; Ryan L; Frei CR
J Natl Med Assoc; 2009 Dec; 101(12):1221-9. PubMed ID: 20070010
[TBL] [Abstract][Full Text] [Related]
10. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
[TBL] [Abstract][Full Text] [Related]
12. HIV-related pneumonia care in older patients hospitalized in the early HAART era.
Sureka A; Parada JP; Deloria-Knoll M; Chmiel JS; Phan L; Lyons TM; Ali S; Yarnold PR; Weinstein RA; Dehovitz JA; Jacobson JM; Goetz MB; Campo RE; Berland D; Bennett CL; Uphold CR
AIDS Patient Care STDS; 2004 Feb; 18(2):99-107. PubMed ID: 15006184
[TBL] [Abstract][Full Text] [Related]
13. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group.
Easterbrook PJ; Keruly JC; Creagh-Kirk T; Richman DD; Chaisson RE; Moore RD
JAMA; 1991 Nov; 266(19):2713-8. PubMed ID: 1942423
[TBL] [Abstract][Full Text] [Related]
14. Participation in research and access to experimental treatments by HIV-infected patients.
Gifford AL; Cunningham WE; Heslin KC; Andersen RM; Nakazono T; Lieu DK; Shapiro MF; Bozzette SA;
N Engl J Med; 2002 May; 346(18):1373-82. PubMed ID: 11986412
[TBL] [Abstract][Full Text] [Related]
15. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease.
Eldred LJ; Wu AW; Chaisson RE; Moore RD
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):117-25. PubMed ID: 9637576
[TBL] [Abstract][Full Text] [Related]
16. High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States.
Gebo KA; Fleishman JA; Reilly ED; Moore RD;
Med Care; 2005 Sep; 43(9 Suppl):III23-30. PubMed ID: 16116306
[TBL] [Abstract][Full Text] [Related]
17. Racial differences in care among hospitalized patients with Pneumocystis carinii pneumonia in Chicago, New York, Los Angeles, Miami, and Raleigh-Durham.
Bennett CL; Horner RD; Weinstein RA; Dickinson GM; DeHovitz JA; Cohn SE; Kessler HA; Jacobson J; Goetz MB; Simberkoff M
Arch Intern Med; 1995 Aug 7-21; 155(15):1586-92. PubMed ID: 7618980
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Pneumocystis carinii pneumonia: who are we missing?
Schwarcz SK; Katz MH; Hirozawa A; Gurley J; Lemp GF
AIDS; 1997 Aug; 11(10):1263-8. PubMed ID: 9256945
[TBL] [Abstract][Full Text] [Related]
19. Application of the nonlinear Blinder-Oaxaca decomposition to study racial/ethnic disparities in antiobesity medication use in the United States.
Mehta HB; Rajan SS; Aparasu RR; Johnson ML
Res Social Adm Pharm; 2013; 9(1):13-26. PubMed ID: 22554395
[TBL] [Abstract][Full Text] [Related]
20. Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy.
Napoli PA; Dorrucci M; Serraino D; Pezzotti P; Franceschi S; Vella S; Rezza G
Eur J Epidemiol; 1998 Jan; 14(1):41-7. PubMed ID: 9517872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
